Apixaban vs rivaroxaban in patients with atrial fibrillation at high or low bleeding risk: A population-based cohort study
Mohammed Shurrab, Peter C. Austin, Cynthia A. Jackevicius, Karen Tu, Feng Qiu, Olivia Haldenby, Steven Davies, Renato D. Lopes, Tina Baykaner, Linda Johnson, Jeff S. Healey, Dennis T. Ko
Topics & Concepts
MedicineRivaroxabanAtrial fibrillationApixabanInternal medicineCardiologyCohortMajor bleedingPopulationWarfarinEnvironmental healthAtrial Fibrillation Management and OutcomesIntracerebral and Subarachnoid Hemorrhage ResearchVenous Thromboembolism Diagnosis and Management